Yahoo · Oct 5, 2026
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in next 30 days SYDNEY, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage radiopharmaceutical company, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S.
